Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Neuphoria (NEUP), 543% surge in interest
• Fusemachines (FUSE), 331% surge in interest
• Summit Therapeutics (SMMT), 107% surge interest

Pipeline and key clinical candidates for these companies:

Neuphoria is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria’s lead drug candidate is BNC210, a first-of-its-kind, well-tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, potentially providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction.

Fusemachines is a global provider of enterprise AI products and services, on a mission to democratize AI. Leveraging proprietary AI Studio and AI Engines, the company helps drive the clients’ AI Enterprise Transformation, regardless of where they are in their Digital AI journeys. With offices in North America, Asia, and Latin America, Fusemachines provides a suite of enterprise AI offerings and specialty services that allow organizations of any size to implement and scale AI. Fusemachines serves companies in industries such as healthcare, finance, retail, manufacturing, and government.

Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Recent news on these stocks:

October 23

Shares of Summit Therapeutics moved higher after its Chief Accounting Officer Bhaskar Anand disclosed the purchase of 26,680 shares at an average price of $18.74, for a total of $499,983. Anand now owns 159,751 shares of Summit.

Fusemachines announced the completion of its business combination with CSLM Acquisition. The newly combined entity will operate under the name Fusemachines. Fusemachines common stock and warrants will begin trading on the Nasdaq Global Market under the symbols “FUSE” and “FUSEW”, respectively, beginning October 23, 2025.

October 22

Summit Therapeutics announced that the company has accepted offers from multiple biotech institutional and individual investors to purchase an aggregate of approximately 26.68M shares of the company’s common stock at $18.74 per share, the closing price on Tuesday, October 21, for aggregate gross and net proceeds to the company of approximately $500M. Robert Duggan, the company’s co-CEO, executive chairman of the board of directors and majority stockholder, Mahkam Zanganeh, co-CEO, president and member of the board, Manmeet Soni, COO, CFO and member of the board, Bhaskar Anand, CAO and certain non-executive employees each participated as Investors in the private placement, investing an aggregate of $272M. Additionally, Akeso participated as an investor in the private placement, investing $10M. Yu Xia, a member of the board, is the CEO and chairwoman of Akeso. Summit’s insiders including Akeso invested a total of $282M. The remaining funds of $218M were raised with multiple leading biopharma institutional investors and other individual investors. Summit intends to use the net proceeds to advance, in part, the clinical development of ivonescimab, in addition to working capital needs and general corporate purposes.

October 21

Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.